Press releases

ORYZON presents preliminary data from ongoing Phase Ib FRIDA trial with iadademstat plus gilteritinib in relapsed/refractory FLT3-mut AML patients at EHA-2024

ORYZON announces journal publication of final Phase IIa ALICE results with iadademstat in The Lancet Haematology

ORYZON to provide corporate progress updates at several events in June

ORYZON selected as Associated Partner in the first Important Project of Common European Interest (IPCEI) in the health sector (Med4Cure project)

ORYZON to provide corporate progress updates at several events in May

ORYZON reports financial results and corporate update for quarter ended March 31, 2024

ORYZON secures another important patent for its lead CNS asset, vafidemstat

ORYZON announces U.S. FDA clearance of CTEP-CRADA Phase I/II clinical trial sponsored by NCI for iadademstat plus immune checkpoint inhibitors in 1L extensive stage Small Cell Lung Cancer

ORYZON to provide corporate progress updates at several events in April

ORYZON receives the INNOVATIVE SME seal from the Spanish Ministry of Science and Innovation